iwCLL 2023

2023 Young Investigator Meeting Agenda

This agenda has been prepared to provide information regarding the upcoming meeting and is subject to change.

8:00 AM

Welcome and Introductions
Welcome & Opening Remarks by Jennifer R. Brown, MD, PhD & Co-Chairs Elisa ten Hacken, PhD, Philip Thompson, BA, BSW, MSW, PhD

Session 1: Pathogenesis of CLL – Session Chairs: Elisa ten Hacken, PhD & Basile Stamatopoulos, PhD

8:10 AM
Oral Presentation
LYN kinase and its regulator CSK as key players in CLL-supporting macrophages
Presenting Author: Viktoria Kohlhas
8:20 AM
Oral Presentation
PI3K inhibitor-resistant B-cell lymphomas show distinct functional phenotypes characterized by sensitivity to Bcl-2- or proteasome-inhibition
Presenting Author: Johanne Hermansen, MSc
8:30 AM
Oral Presentation
The RNA-binding protein Musashi2 is regulated by NOTCH1/KLF4 pathway and support tumor survival keeping CLL cells in proliferative niches during disease progression
Presenting Author: Juliana Querol Rivas
8:40 AM
Oral Presentation
ZMYM3 Mutations Dysregulate Histone Acetylation and Impact the Outcome Of Chronic Lymphocytic Leukemia Patients
Presenting Author: Alberto Rodríguez Sánchez, BSc
8:50 AM
Oral Poster
Inhibition of G protein-coupled receptor kinase 2 (GRK2) as a strategy to modulate leukemic cell homing and activation in CLL
Presenting Author: Mercedes Borge, PhD
8:55 AM
Oral Poster
m6A-modified circTET2 interacting with HNRNPC regulates fatty acid oxidation to promote the proliferation of chronic lymphocytic leukemia
Presenting Author: Hui Jin, MD
9:00 AM
Oral Poster
Refining the phenotypic and functional intraclonal complexity in chronic lymphocytic leukemia B cells uncovers a discrepancy between surface membrane IG levels and time since birth supporting the requirement for multifactorial activation and different subclonal sensitivities to treatment.
Presenting Author: Andrea Mazzarello, PhD
9:05 AM
Oral Poster
Transcription factor FoxO1 Mediates Adaptive Increase in Akt Activity and Cell Survival During BCR Inhibitor Therapy in CLL
Presenting Author: Marek Mraz, MD, PhD
9:10 AM
Session Panel Discussion
9:20 AM
Session 2: Translational Research of CAR T-Cells – Session Chair: William Wierda, MD, PhD
9:35 AM
Oral Presentation
Combining CD19 CAR T cells with T cell-engaging bispecific antibody treatment enhances efficacy in murine models of CLL and ex vivo patient cultures
Presenting Author: Alessia Floerchinger, MSc
9:45 AM
Oral Presentation
Expression of SIGLEC-10 ligands CD24 and CD52 limit T cell and CAR-T cell function in CLL
Presenting Author: Fleur S. Peters, PhD
9:55 AM
Oral Presentation
Generation and preclinical evaluation of a novel ROR1-specific CAR T-cells against chronic lymphocytic leukemia
Presenting Author: Md Kamrul Hasan, PhD
10:05 AM
Session Panel Discussion
10:15 AM

Session 3: Translational Research in CLL – Session Chairs: Fleur Peters, PhD & Marek Mraz, MD, PhD

10:25 AM
Oral Presentation
Increased susceptibility to Streptococcus pneumoniae pulmonary infection in the Eµ-TCL1 adoptive transfer mouse model of CLL
Presenting Author: Ana Colado, PhD
10:35 AM
Oral Presentation
NX-2127 and NX-5948, two clinical stage cereblon-recruiting BTK degraders, facilitate T-cell functionality in CLL
Presenting Author: Tiana Huynh
10:45 AM
Oral Presentation
Single-cell transcriptomic analysis of CLL cells at ibrutinib plus venetoclax relapse and targeting using BCL-2/BCL-xL PROTACs PZ18753b and WH25244
Presenting Author: Daisy Diaz Rohena, BS
10:55 AM
Oral Presentation
T-cell Transcriptional and Mitochondrial Fitness Reprogramming in CLL Using PI3Kδ Inhibitors
Presenting Author: Wael Gamal, MSc
11:05 AM
Oral Poster
Identification of novel targets that upregulate CD20 expression in rituximab-resistant cells with the use of genome-wide CRISPR screening
Presenting Author: Lenka Dostálová, MSc
11:10 AM
Oral Poster
Integrating Multi-Omics to Reveal the Heterogeneous Clonal Evolutionary Characteristics in CLL Patients with Zanubrutinib Resistance
Presenting Author: Huayuan Zhu, MD
11:15 AM
Oral Poster
Single-cell RNA sequencing Reveals the Spatial Heterogeneity in BTKi-Resistant Richter Transformation Patients
Presenting Author: Huayuan Zhu, MD
11:20 AM
Oral Poster
T cell type abundance and gene expression patterns in the context of clinical progression of treatment-naïve CLL/MBL patients from the OxPLoreD study
Presenting Author: Grigore-Aristide Gafencu, BMBS, DPhil
11:25 AM
Oral Poster
The PKCβ inhibitor MS-553 displays preclinical efficacy in BTK inhibitor resistant Chronic Lymphocytic Leukemia
Presenting Author: Britten Gordon, BS
11:30 AM
Oral Poster
Toll-like receptor 9 signalling in CLL: a resistance mechanism to B-cell receptor-targeted treatments, and a potential tool for therapeutic stratification.
Presenting Author: Emma Kennedy, PhD
11:35 AM
Oral Poster
XPO1 mutations identify early stage CLL characterized by shorter time to first treatment and enhanced BCR signaling
Presenting Author: Riccardo Moia, MD
11:40 AM
Session Panel Discussion
11:50 AM
Session 4: Approach Considerations and Treatment Options in CLL – Session Chairs: Kerry Rogers, MD & Philip Thompson, BA, BSW, MSW, PhD
12:30 PM
Oral Presentation
A Study of Frontline Therapy in Adults Aged 80+ Years with Chronic Lymphocytic Leukemia (CLL)
Presenting Author: Mazie Tsang, MD, MAS, MS
12:40 PM
Oral Presentation
Clinical outcomes in patients with chronic lymphocytic leukemia (CLL) treated with venetoclax-based regimens
Presenting Author: Paul Hampel, MD
12:50 PM
Oral Presentation
Explainable Machine Learning to Identify Chronic Lymphocytic Leukemia Based on Gut Microbiome Data
Presenting Author: Carsten Niemann, MD, PhD
1:00 PM
Oral Presentation
Mutations and translocations associated with venetoclax resistance in chronic lymphocytic leukemia (CLL)
Presenting Author: Kiyomi Mashima, MD, PhD
1:10 PM
Oral Presentation
Sensitive monitoring of sequential targeted therapy resistance in relapsed/therapy refractory chronic lymphocytic leukemia
Presenting Author: Lili Kotmayer, MD, PhD
1:20 PM
Oral Presentation
Single center report on cohort of patients relapsed on Bruton Tyrosine Kinase inhibitors (BTKi)
Presenting Author: Huayuan Zhu, MD
1:30 PM
Oral Presentation
Time-limited venetoclax-rituximab is effective for patients with Bruton tyrosine kinase exposed chronic lymphocytic leukaemia, but durable treatment-free remissions are uncommon
Presenting Author: Thomas Lew, MBBS
1:40 PM
Oral Poster
Association between hypertension and overall survival in chronic lymphocytic leukemia
Presenting Author: Noomi Vainer, MD
1:45 PM
Oral Poster
Changes in immune cell numbers and profile during long-term zanubrutinib treatment in treatment-naïve and relapsed/refractory patients with chronic lymphocytic leukemia
Presenting Author: Maria Andersson, MD
1:50 PM
Oral Poster
Impact of COVID-19 in patients with Chronic Lymphocytic Leukemia treated with venetoclax: a possible role of the association to anti-CD20 antibody? A multicentre SEIFEM study.
Presenting Author: Francesco Autore, MD, PhD
1:55 PM
Session Panel Discussion
2:05 PM

Keynote and YIM Award Presentations – Session Chairs: Elisa ten Hacken, PhD & Basile Stamatopoulos, PhD

2:20 PM
Keynote Presentation: Anna Schuh, MD, PhD
2:50 PM

Awards / Concluding Remarks

3:05 PM